PSY89 Cost Effectiveness of Ruxolitinib Versus Best Available Therapy For The Treatment of Myelofibrosis From Public Health Perspective In Chile

Rojas, R Balmaceda, C Vargas, C Espinoza, M

Permalink

Closed Access

	Filename	Description	Size
	Cost Effectiveness ...pdf	Published version	303.33 kB		View/Open

Copyright Clearance Process

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Rojas, R
dc.contributor.author	Balmaceda, C
dc.contributor.author	Vargas, C
dc.contributor.author	Espinoza, M
dc.date.accessioned	2025-01-24T04:25:50Z
dc.date.available	2025-01-24T04:25:50Z
dc.date.issued	2016-11
dc.identifier.citation	Value in Health, 2016, 19, (7), pp. a590
dc.identifier.issn	1098-3015
dc.identifier.uri	http://hdl.handle.net/10453/184182
dc.language	en
dc.publisher	Elsevier
dc.relation.ispartof	Value in Health
dc.relation.isbasedon	10.1016/j.jval.2016.09.1404
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1117 Public Health and Health Services, 1402 Applied Economics
dc.subject.classification	Health Policy & Services
dc.subject.classification	3801 Applied economics
dc.subject.classification	4203 Health services and systems
dc.subject.classification	4407 Policy and administration
dc.title	PSY89 Cost Effectiveness of Ruxolitinib Versus Best Available Therapy For The Treatment of Myelofibrosis From Public Health Perspective In Chile
dc.type	Journal Article
utslib.citation.volume	19
utslib.for	1117 Public Health and Health Services
utslib.for	1402 Applied Economics
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Health
utslib.copyright.status	closed_access	*
dc.date.updated	2025-01-24T04:25:49Z
pubs.issue	7
pubs.publication-status	Published
pubs.volume	19
utslib.citation.issue	7

Please use this identifier to cite or link to this item: